ArticleJournal of cancer research and clinical oncology2017
Presence of sarcomatoid differentiation as a prognostic indicator for survival in surgically treated metastatic renal cell carcinoma.
Article in Journal of cancer research and clinical oncology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Prognostic Significance of Sarcomatoid Differentiation in Patients With Metastatic Renal Cell Carcinoma: A Systematic Review and Meta-Analysis.Frontiers in oncology · 2020Pooled it
- Tumor necrosis as a prognostic variable for the clinical outcome in patients with renal cell carcinoma: a systematic review and meta-analysis.BMC cancer · 2018Pooled it
- Repurposing Seleno-L-Methionine as a Pleiotropic Immunomodulatory Agent to Overcome TGF-β1/HIF-Driven Immune Evasion in Clear Cell Renal Cell Carcinoma: Mechanistic Insights and Translational Therapeutic Opportunities.International journal of molecular sciences · 2026Review
- Sarcomatoid Renal Cell Carcinoma: A Clinical Review.Diagnostics (Basel, Switzerland) · 2026Review
- Severe Metabolic Decompensation in Metastatic Sarcomatoid Renal Cell Carcinoma During Immune Checkpoint Inhibitor Therapy: A Case Report and Literature Review.Diagnostics (Basel, Switzerland) · 2026Article
- Review
- Targeted gene sequencing reveals disparate genomic mutations between young and older adults in renal cell carcinoma.BMC cancer · 2024Article
- Prognostic significance of sarcomatoid features in metastatic renal cell carcinoma treated with cytoreductive nephrectomy and targeted therapy.American journal of clinical and experimental urology · 2022Article
- Sarcomatoid renal cell carcinoma: biology, natural history and management.Nature reviews. Urology · 2020Review
- Impact of sarcomatoid differentiation and rhabdoid differentiation on prognosis for renal cell carcinoma with vena caval tumour thrombus treated surgically.BMC urology · 2020Article
- The Association Between Small Primary Tumor Size and Prognosis in Metastatic Renal Cell Carcinoma: Insights from Two Independent Cohorts of Patients Who Underwent Cytoreductive Nephrectomy.European urology oncology · 2020Article
- The Role of Cytoreductive Nephrectomy for Sarcomatoid Renal Cell Carcinoma: A 29-Year Institutional Experience.Urology · 2020Article
- Kidney Cancer Research Network of Canada (KCRNC) consensus statement on the role of cytoreductive nephrectomy for patients with metastatic renal cell carcinoma.Canadian Urological Association journal = Journal de l'Association des urologues du Canada · 2019Article
- Epidemiology, biology and treatment of sarcomatoid RCC: current state of the art.World journal of urology · 2019Review
- The prognostic value and clinicopathological features of sarcomatoid differentiation in patients with renal cell carcinoma: a systematic review and meta-analysis.Cancer management and research · 2018Article
- Rapid recurrence and radiographic progression of sarcomatoid renal cell carcinoma.Urology case reports · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo assess the prognostic significance of sarcomatoid differentiation for surgically treated metastatic renal cell carcinoma (mRCC).
methodsPatients undergoing cytoreductive nephrectomy for mRCC in our center between 2006 and 2014 were included. All enrolled patients were separated into two groups according to the presence of sarcomatoid differentiation. Clinical and pathological variables were recorded. Student's t test or Chi-square test was applied to compare them. Univariate and multivariate Cox regression were performed to determine independent prognostic factors for oncologic outcomes.
resultsOf the 184 patients with mRCC included, 27 (14.7%) patients presented with sarcomatoid differentiation. The presence of sarcomatoid differentiation was associated with higher rates of non-clear cell histology (P = 0.009), higher Fuhrman grade (P < 0.001), higher rates of presenting tumor necrosis (P = 0.005), worse IMDC risk group (P = 0.022), and MSKCC risk group (P = 0.020). Patients with sarcomatoid differentiation showed shorter median progression-free survival and overall survival. Multivariate analysis identified that sarcomatoid differentiation was independently associated with progression-free survival (hazard ratio [HR]: 2.002, 95% CI 1.047-3.828; P = 0.036) and overall survival (HR: 1.922, 95% CI 1.073-3.445; P = 0.028). Sarcomatoid differentiation remained to be independently associated with inferior PFS (HR: 2.097, 95% CI 1.091-4.030; P = 0.026) and OS (HR: 2.245, 95% CI 1.276-3.951; P = 0.005) for clear cell mRCC.
conclusionThe presence of sarcomatoid differentiation is independently associated with poor oncologic outcomes for surgically treated mRCC patients. The association remains significant when the subject of study is restricted to clear cell mRCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.